论文部分内容阅读
目的观察孟鲁司特治疗哮喘的疗效及其对患者炎性因子、肺功能的影响。方法将哮喘患者89例随机分为观察组45例和对照组44例,对照组给予常规治疗,观察组在对照组治疗的基础上给予孟鲁司特治疗,比较2组患者临床疗效、治疗前后肺功能、炎性因子水平。结果观察组总有效率为97.8%明显高于对照组的88.6%,差异有统计学意义(P<0.05)。入院时2组肺功能指标比较差异无统计学意义(P>0.05),用药后2组肺功能均改善,且观察组优于对照组,差异均有统计学意义(P<0.05)。2组入院时肿瘤坏死因子(TNF-α)、白介素-10(IL-10)水平比较差异无统计学意义(P>0.05),用药后2组TNF-α、IL-10水平均明显改善,且观察组优于对照组,差异均有统计学意义(P<0.05)。结论孟鲁司特治疗哮喘疗效显著,能有效改善患者气道炎性反应及肺功能,值得临床推广应用。
Objective To observe the curative effect of montelukast on asthma and its effect on inflammatory factors and pulmonary function in patients. Methods Eighty-nine asthmatic patients were randomly divided into observation group (n = 45) and control group (n = 44). The control group was given routine treatment. The observation group was treated with montelukast on the basis of the control group. The clinical efficacy was compared between the two groups. Pulmonary function, level of inflammatory cytokines. Results The total effective rate was 97.8% in the observation group was significantly higher than 88.6% in the control group, the difference was statistically significant (P <0.05). There was no significant difference in the lung function indexes between the two groups on admission (P> 0.05). The pulmonary function of the two groups were improved after treatment, and the observation group was superior to the control group (P <0.05). The levels of tumor necrosis factor (TNF-α) and interleukin-10 (IL-10) in the two groups were not significantly different at admission (P> 0.05). The levels of TNF-α and IL- The observation group was better than the control group, the differences were statistically significant (P <0.05). Conclusion Montelukast treatment of asthma significant effect, can effectively improve the airway inflammatory response and pulmonary function, worthy of clinical application.